Salud financiera de hoja de balance de Cellectis

Salud financiera controles de criterios 5/6

Cellectis tiene un patrimonio de los accionistas total de $76.1M y una deuda total de $31.5M, lo que sitúa su ratio deuda-patrimonio en 41.4%. Sus activos y pasivos totales son $209.7M y $133.6M respectivamente.

Información clave

64.2%

Ratio deuda-patrimonio

US$54.41m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$136.71m
Patrimonio	US$84.70m
Total pasivo	US$249.58m
Activos totales	US$334.27m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($96.5M) de ZVA superan a sus pasivos a corto plazo ($44.0M).

Pasivo a largo plazo: Los activos a corto plazo de ZVA ($96.5M) superan a sus pasivos a largo plazo ($89.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ZVA tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de ZVA ha crecido de 0% a 41.4% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ZVA tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ZVA dispone de suficiente cash runway para 1.5 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 4.6% cada año.

Salud financiera de hoja de balance de Cellectis

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Cellectis Announces Chief Financial Officer Changes

Full year 2023 earnings released: US$1.92 loss per share (vs US$1.99 loss in FY 2022)

No longer forecast to breakeven

Cellectis S.A. to Report Q1, 2024 Results on May 09, 2024

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis S.A. Announces Board Appointments

New major risk - Shareholder dilution

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.63 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Cellectis S.A. to Report Q3, 2023 Results on Nov 06, 2023

Less than half of directors are independent

Less than half of directors are independent

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of A Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

Second quarter 2023 earnings released: US$0.09 loss per share (vs US$0.42 loss in 2Q 2022)

Cellectis S.A. to Report Q2, 2023 Results on Aug 03, 2023

Cibus Global, Ltd. completed the acquisition of Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cellectis S.A., Annual General Meeting, Jun 27, 2023

Cellectis S.A. Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T- Cells at ASGCT 2023

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on A Novel Treatment Paradigm for Successful Car T Immunotherapy Against Stroma-Rich Solid Tumors

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Full year 2022 earnings released: US$1.99 loss per share (vs US$2.55 loss in FY 2021)

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Cellectis S.A. has completed a Follow-on Equity Offering in the amount of $22 million.

Now 26% undervalued after recent price drop

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cellectis S.A. announced that it has received $20 million in funding from Cytovia Therapeutics, Inc.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Now 24% undervalued

Insufficient new directors

Cellectis S.A. Announces the Resignation of Alain Godard as a Member of the Board

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Cellectis S.A Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.82 loss in 3Q 2021)

Cellectis to Showcase Clinical Data from Ameli-01 and Preclinical Data from Ucartcs1 At Ash 2022

Cellectis S.A. to Report Q3, 2022 Results on Nov 03, 2022

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Cellectis Appoints Mark Frattini as Chief Medical Officer

Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.88 loss in 2Q 2021)

Cellectis S.A. Announces Executive Changes

Cellectis S.A. Announces U.S. Food and Drug Administration Clear Cellectis’ Investigational New Drug Application to Initiate A Phase 1/2A Clinical Trial of UCART20x22 for Patients

Cellectis S.A. to Report Q2, 2022 Results on Aug 04, 2022

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis S.A., Annual General Meeting, Jun 28, 2022

Cellectis Presents Research Data on A Novel Immune-Evasive Universal CAR T-Cell At ASGCT

First quarter 2022 earnings released: US$0.70 loss per share (vs US$0.28 loss in 1Q 2021)

Cellectis S.A. to Report Q1, 2022 Results on May 12, 2022

Cellectis S.A. Releases Preclinical Data on Its Product Candidate UCART20x22 At the American Association for Cancer Research Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Cellectis S.A. to Report Q4, 2021 Results on Mar 03, 2022

Cellectis Appoints Bing C. Wang as Member of its Executive Committee

Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Senior Vice President of Technical Operations - Europe Leopold Bertea has left the company

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.71 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.76 loss in 2Q 2020)

Cellectis S.A. Announces New Product Candidate Pipeline, and Manufacturing and Technologies

First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.47 profit in 1Q 2020)

Cellectis S.A. Announces Preliminary Results from its Phase 1 Balli-01 Clinical Study of Ucart22 in Adults with R/R B-All Presented in Oral Session At 2020 Ash Annual Meeting

Full year 2020 earnings released: US$1.91 loss per share (vs US$2.41 loss in FY 2019)

Revenue beats expectations

Cellectis S.A. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day low: €18.20

Cytovia Therapeutics, Inc. and Cellectis Enter into Strategic Research and Development Collaboration

New 90-day high: €27.45

New 90-day high: €25.85

New 90-day high: €25.65

New 90-day high: €18.66

FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma

Cellectis Appoints Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

Revenue misses expectations

Third quarter 2020 earnings released: US$0.71 loss per share

Cellectis S.A. Appoints Jean-Pierre Garnier, Ph.D as Non-Executive Chairman of the Board of Directors

New 90-day low: €13.54